| ORIGINAL ARTICLE |
|
| Year : 2018 | Volume
: 13
| Issue : 1 | Page : 30-35 |
|
|
Primary pulmonary lymphoepithelioma-like carcinoma in Singapore
Chee Kiang Tay1, Yang Chong Chua2, Angela Takano3, Madeline Yen Min Chee4, Wan-Teck Lim5, Cindy Lim6, Mariko Siyue Koh7
1 Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore
2 Division of Surgical Oncology, National Cancer Center, Singapore
3 Department of Pathology, Singapore General Hospital, Singapore
4 Faculty of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
5 Division of Medical Oncology, National Cancer Center; Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre, Singapore
6 Faculty of Medicine, Duke-National University Singapore Medical School, Singapore
7 Department of Respiratory and Critical Care Medicine, Singapore General Hospital; Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre, Singapore
Correspondence Address:
Dr. Mariko Siyue Koh
Department of Respiratory and Critical Care Medicine, Singapore General Hospital, 20 College Road, Academia, Level 3, 169 856
Singapore
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/atm.ATM_304_17
|
|
|
BACKGROUND: Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) is a rare subtype of nonsmall cell lung cancer (NSCLC) predominantly reported in East Asia. We aimed to evaluate clinical characteristics, diagnosis, treatment, and prognosis of PPLELC in Singapore.
METHODS: Retrospective review of all patients diagnosed with PPLELC at our center between 2000 and 2014.
RESULTS: All 28 patients were Chinese, 67.9% were female, and the median age was 58 years (range37–76 years). Majority (89.3%) were never smokers and 53.6% asymptomatic at diagnosis. About 28.6% presented with Stage I/II disease, 25% had Stage III disease, and 46.4% had Stage IV disease. All patients with Stage I/II disease underwent lobectomy without adjuvant treatment. Four out of 7 patients with Stage III disease underwent surgery with or without adjuvant therapy while the rest received chemoradiation. Twelve out of 13 patients with Stage IV disease received chemotherapy with or without radiotherapy. At the end of 2016, survival data were available for all 28 patients. Two-year survival rates for Stage I/II, Stage III, and Stage IV disease were 100%, 85.7%, and 61.5%, respectively, while survival was 100%, 85.7%, and 9.6%, respectively, at five years.
CONCLUSION: The majority (46.4%) of patients presented with metastatic disease. For those with Stage I-III disease, 5-year survival for PPLELC was better than other NSCLC subtypes. Multimodality treatment including surgery could be considered in locally advanced disease. In Stage IV disease, it tended to approximate that of NSCLC.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
